MX2010009844A - Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento. - Google Patents
Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento.Info
- Publication number
- MX2010009844A MX2010009844A MX2010009844A MX2010009844A MX2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A
- Authority
- MX
- Mexico
- Prior art keywords
- ziprasidone
- human
- kits
- dosage forms
- cns disorder
- Prior art date
Links
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 7
- 229960000607 ziprasidone Drugs 0.000 title abstract 7
- 239000002552 dosage form Substances 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 abstract 3
- 210000002966 serum Anatomy 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 229940100691 oral capsule Drugs 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona procedimientos, formas farmacéuticas y kits para tratar con una cantidad eficaz de ziprasidona un trastorno del SNC en un ser humano cuando el ser humano está en estado de ayunas. En una realización, la invención se refiere a un procedimiento para tratar un trastorno del SNC en un ser humano, procedimiento que comprende administrar al ser humano en estado de ayunas, una forma farmacéutica oral sólida que comprende una cantidad de ziprasidona eficaz para tratar dicho trastorno del SNC, en el que el área bajo la curva de concentración en suero en función del tiempo (ABC0-inf) de la ziprasidona en el ser humano posterior a dicha administración es del 70% al 140% del área media bajo la curva de concentración de ziprasidona en suero en función del tiempo (ABC0-inf) que resulta de la administración de una cápsula oral de ziprasidona de liberación inmediata de control que contiene la misma cantidad de ziprasidona a una cohorte de seres humanos en estado alimentado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3494708P | 2008-03-07 | 2008-03-07 | |
| PCT/IB2009/000442 WO2009109844A1 (en) | 2008-03-07 | 2009-03-04 | Methods, dosage forms, and kits for administering ziprasidone without food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010009844A true MX2010009844A (es) | 2010-09-30 |
Family
ID=40720011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010009844A MX2010009844A (es) | 2008-03-07 | 2009-03-04 | Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110002989A1 (es) |
| EP (1) | EP2280711A1 (es) |
| JP (1) | JP2009215293A (es) |
| KR (1) | KR20100131477A (es) |
| CN (1) | CN102014910A (es) |
| AR (1) | AR070964A1 (es) |
| AU (1) | AU2009220925A1 (es) |
| BR (1) | BRPI0909818A2 (es) |
| CA (1) | CA2719115A1 (es) |
| IL (1) | IL207792A0 (es) |
| MX (1) | MX2010009844A (es) |
| RU (1) | RU2010135831A (es) |
| TW (1) | TW200950783A (es) |
| WO (1) | WO2009109844A1 (es) |
| ZA (1) | ZA201005905B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010082855A1 (en) * | 2009-01-15 | 2010-07-22 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation |
| US9510148B2 (en) * | 2009-03-03 | 2016-11-29 | Mobilitie, Llc | System and method for wireless communication to permit audience participation |
| HK1223547A1 (zh) * | 2013-05-03 | 2017-08-04 | 欣达克斯制药公司 | 癌症治疗方法 |
| KR20160036590A (ko) | 2013-07-30 | 2016-04-04 | 질레드 코네티컷 인코포레이티드 | Ｓｙｋ 억제제의 제제 |
| ES2822285T3 (es) | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | Polimorfo de inhibidores de SYK |
| WO2015082562A1 (en) * | 2013-12-05 | 2015-06-11 | Alrise Biosystems Gmbh | Process for the production of drug formulations for oral administration |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| US10474345B2 (en) * | 2014-04-04 | 2019-11-12 | Shawn SHEY | User interfaces and methods for displaying content |
| CN106714785A (zh) * | 2014-09-19 | 2017-05-24 | 宝洁公司 | 用于制备具有活性包衣的芯的方法 |
| WO2016198983A1 (en) | 2015-06-09 | 2016-12-15 | Bend Research Inc. | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| CA2987081C (en) | 2015-06-11 | 2022-08-30 | Alrise Biosystems Gmbh | Process for the preparation of drug loaded microparticles |
| CN107714669A (zh) * | 2016-08-11 | 2018-02-23 | 广东东阳光药业有限公司 | 齐拉西酮缓释剂及其制备方法 |
| US11384082B2 (en) | 2017-08-25 | 2022-07-12 | Kronos Bio, Inc. | Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors |
| CA3130848A1 (en) | 2019-02-22 | 2020-08-27 | Kronos Bio, Inc. | Solid forms of condensed pyrazines as syk inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030170309A1 (en) * | 2001-06-22 | 2003-09-11 | Babcock Walter C. | Pharmaceutical compositions containing polymer and drug assemblies |
| KR20080093464A (ko) * | 2003-09-02 | 2008-10-21 | 화이자 프로덕츠 인크. | 지프라시돈 나노입자 |
| US7825106B2 (en) * | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
| WO2005065660A2 (en) * | 2003-12-31 | 2005-07-21 | Alpharma, Inc. | Ziprasidone formulations |
| WO2005123086A2 (en) * | 2004-06-11 | 2005-12-29 | Dr. Reddy's Laboratories Ltd. | Ziprasidone dosage form |
| BRPI0612297A2 (pt) * | 2005-06-20 | 2010-11-03 | Elan Pharma Int Ltd | composição de nanoparticulado estável, método para prepará-la, uso da mesma, composição farmacêutica, uso da mesma, forma de dosagem, composição de liberação controlada, e, uso da mesma |
-
2009
- 2009-03-04 EP EP09717510A patent/EP2280711A1/en not_active Withdrawn
- 2009-03-04 AU AU2009220925A patent/AU2009220925A1/en not_active Abandoned
- 2009-03-04 BR BRPI0909818A patent/BRPI0909818A2/pt not_active IP Right Cessation
- 2009-03-04 TW TW098106972A patent/TW200950783A/zh unknown
- 2009-03-04 MX MX2010009844A patent/MX2010009844A/es not_active Application Discontinuation
- 2009-03-04 US US12/920,400 patent/US20110002989A1/en not_active Abandoned
- 2009-03-04 CA CA2719115A patent/CA2719115A1/en not_active Abandoned
- 2009-03-04 RU RU2010135831/15A patent/RU2010135831A/ru not_active Application Discontinuation
- 2009-03-04 KR KR1020107022343A patent/KR20100131477A/ko not_active Ceased
- 2009-03-04 WO PCT/IB2009/000442 patent/WO2009109844A1/en not_active Ceased
- 2009-03-04 CN CN2009801164839A patent/CN102014910A/zh active Pending
- 2009-03-06 AR ARP090100819A patent/AR070964A1/es not_active Application Discontinuation
- 2009-03-06 JP JP2009052853A patent/JP2009215293A/ja not_active Withdrawn
-
2010
- 2010-08-18 ZA ZA2010/05905A patent/ZA201005905B/en unknown
- 2010-08-24 IL IL207792A patent/IL207792A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009220925A1 (en) | 2009-09-11 |
| RU2010135831A (ru) | 2012-04-20 |
| TW200950783A (en) | 2009-12-16 |
| AR070964A1 (es) | 2010-05-19 |
| WO2009109844A1 (en) | 2009-09-11 |
| ZA201005905B (en) | 2011-11-30 |
| BRPI0909818A2 (pt) | 2015-10-06 |
| CA2719115A1 (en) | 2009-09-11 |
| EP2280711A1 (en) | 2011-02-09 |
| JP2009215293A (ja) | 2009-09-24 |
| KR20100131477A (ko) | 2010-12-15 |
| CN102014910A (zh) | 2011-04-13 |
| IL207792A0 (en) | 2010-12-30 |
| US20110002989A1 (en) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010009844A (es) | Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento. | |
| MX2010008720A (es) | Composiciones, metodos y estuches para mejorar la respuesta inmunitaria a una enfermedad respiratoria. | |
| MX2009011949A (es) | Inhibidores de proteina activadora de 5-lipoxigenasa (flap). | |
| MX2010003884A (es) | Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos. | |
| UA101309C2 (ru) | Антагонисты активина-actrii и их применение для повышения уровня эритроцитов | |
| SG166813A1 (en) | 5-lipoxygenase-activating protein (flap) inhibitors | |
| ATE449602T1 (de) | Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen | |
| MY156316A (en) | Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products | |
| PT1957061E (pt) | Combinação compreendendo, pelo menos, um aminoácido e um inibidor de pkr para utilização no tratamento da perda muscular | |
| MX2011012072A (es) | Lactoferrina y salud y desarrollo neuronal en el intestino infantil. | |
| SG10201407403UA (en) | Treatments For Gastrointestinal Disorders | |
| WO2012145651A3 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| MX2010002410A (es) | Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te. | |
| GB0001449D0 (en) | Compositions | |
| SG165387A1 (en) | 5-lipoxygenase-activating protein (flap) inhibitors | |
| Vieyra-Reyes et al. | Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression | |
| MX2009003518A (es) | Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar. | |
| WO2008007227A3 (en) | Method and compositions for relieving menopausal and perimenopausal symptoms | |
| BRPI0507645A (pt) | anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico | |
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| MX2010001116A (es) | Derivados novedosos de benzamidina, proceso para la preparacion de estos y composicion farmaceutica para la prevencion o el tratamiento de osteoporosis que comprende a los mismos. | |
| MY161853A (en) | Pharmaceutical composition and method for treating hypertension | |
| TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders | |
| EP2098225B8 (en) | Taste masking system for non-plasticizing drugs | |
| BRPI0503827A (pt) | métodos para prevenir ou tratar infecções respiratórias em lactentes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |